TickerFacts.

A business in context

AGIO research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-07 · 8010 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-08-04 · 0001439222-26-000120

  2. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001439222-26-000118

  3. 8-K · Current report

    Report date 2026-07-30 · 0001439222-26-000115 · Items 2.02,9.01

  4. 4 · Ownership change

    Report date 2026-07-08 · 0001439222-26-000112

  5. 4 · Ownership change

    Report date 2026-07-01 · 0001439222-26-000110

  6. 4 · Ownership change

    Report date 2026-06-18 · 0001439222-26-000107

  7. 4 · Ownership change

    Report date 2026-06-18 · 0001439222-26-000105

  8. 4 · Ownership change

    Report date 2026-06-18 · 0001439222-26-000103

  9. 4 · Ownership change

    Report date 2026-06-18 · 0001439222-26-000101

  10. 4 · Ownership change

    Report date 2026-06-18 · 0001439222-26-000099

  11. 8-K · Current report

    Report date 2026-06-18 · 0001193125-26-275879 · Items 5.02,5.07,9.01

  12. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001439222-26-000073

  13. 8-K · Current report

    Report date 2026-04-29 · 0001439222-26-000071 · Items 2.02,9.01

  14. DEF 14A · Proxy statement

    Report date 2026-06-18 · 0001193125-26-177086

  15. 10-K · Annual report

    Report date 2025-12-31 · 0001439222-26-000025

  16. 8-K · Current report

    Report date 2026-02-12 · 0001439222-26-000023 · Items 2.02,9.01

  17. 8-K · Current report

    Report date 2026-01-12 · 0001439222-26-000018 · Items 7.01,9.01

  18. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001439222-25-000116

  19. 8-K · Current report

    Report date 2025-10-30 · 0001439222-25-000114 · Items 2.02,9.01

  20. 8-K · Current report

    Report date 2025-08-04 · 0001439222-25-000090 · Items 7.01

  21. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001439222-25-000089

  22. 8-K · Current report

    Report date 2025-07-31 · 0001439222-25-000087 · Items 2.02,9.01

  23. 8-K · Current report

    Report date 2025-07-03 · 0001439222-25-000076 · Items 5.02

  24. 8-K · Current report

    Report date 2025-06-18 · 0001193125-25-142745 · Items 5.02,5.07,9.01

  25. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001439222-25-000036

  26. 8-K · Current report

    Report date 2025-05-01 · 0001439222-25-000034 · Items 2.02,9.01

  27. DEF 14A · Proxy statement

    Report date 2025-06-18 · 0001193125-25-096719

  28. 10-K · Annual report

    Report date 2024-12-31 · 0001439222-25-000009

  29. 8-K · Current report

    Report date 2025-02-13 · 0001439222-25-000007 · Items 2.02,9.01

  30. 8-K · Current report

    Report date 2025-02-10 · 0001193125-25-025524 · Items 5.02

  31. 8-K · Current report

    Report date 2025-01-13 · 0001193125-25-004943 · Items 7.01,9.01

  32. 8-K · Current report

    Report date 2025-01-03 · 0001193125-25-001809 · Items 7.01

  33. SC 13G/A · Ownership disclosure

    0001172661-24-005116

  34. SC 13G/A · Ownership disclosure

    0000908834-24-000295

  35. 10-Q · Quarterly report

    Report date 2024-09-30 · 0001439222-24-000138

  36. 8-K · Current report

    Report date 2024-10-31 · 0001439222-24-000136 · Items 2.02,9.01

  37. 10-Q · Quarterly report

    Report date 2024-06-30 · 0001439222-24-000121

  38. 8-K · Current report

    Report date 2024-08-01 · 0001439222-24-000117 · Items 2.02,9.01

  39. 8-K · Current report

    Report date 2024-06-20 · 0001193125-24-164555 · Items 5.07

  40. 8-K · Current report

    Report date 2024-05-24 · 0001193125-24-147583 · Items 1.01,8.01,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 7 transaction rows7SGrant / award: 24 transaction rows24AExercise / conversion: 40 transaction rows40MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

71 matching transaction rows. Showing 51–71.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-04-02
2026-04-06
Burns James William
10b5-1 checkbox reported
M · Exercise / conversion
Acquired
Common stock8500.00.0
2026-04-02
2026-04-06
Burns James William
10b5-1 checkbox reported
S · Sale
Disposed
Common stock3280.034.71
2026-04-02
2026-04-06
Burns James William
10b5-1 checkbox reported
M · Exercise / conversion
Disposed
Performance share units
Derivative security
8500.00.0
2026-04-02
2026-04-06
Gheuens Sarah
10b5-1 checkbox reported
M · Exercise / conversion
Acquired
Common stock8500.00.0
2026-04-02
2026-04-06
Gheuens Sarah
10b5-1 checkbox reported
S · Sale
Disposed
Common stock2940.034.71
2026-04-02
2026-04-06
Gheuens Sarah
10b5-1 checkbox reported
M · Exercise / conversion
Disposed
Performance share units
Derivative security
8500.00.0
2026-04-02
2026-04-06
Jones Cecilia
10b5-1 checkbox reported
M · Exercise / conversion
Acquired
Common stock8500.00.0
2026-04-02
2026-04-06
Jones Cecilia
10b5-1 checkbox reported
S · Sale
Disposed
Common stock3141.034.71
2026-04-02
2026-04-06
Jones Cecilia
10b5-1 checkbox reported
M · Exercise / conversion
Disposed
Performance share units
Derivative security
8500.00.0
2026-04-02
2026-04-06
Milanova Tsveta
10b5-1 checkbox reported
M · Exercise / conversion
Acquired
Common stock8500.00.0
2026-04-02
2026-04-06
Milanova Tsveta
10b5-1 checkbox reported
S · Sale
Disposed
Common stock3262.034.71
2026-04-02
2026-04-06
Milanova Tsveta
10b5-1 checkbox reported
M · Exercise / conversion
Disposed
Performance share units
Derivative security
8500.00.0
2026-04-02
2026-04-06
Viswanadhan Krishnan
10b5-1 checkbox reported
M · Exercise / conversion
Acquired
Common stock8100.00.0
2026-04-02
2026-04-06
Viswanadhan Krishnan
10b5-1 checkbox reported
S · Sale
Disposed
Common stock2959.034.71
2026-04-02
2026-04-06
Viswanadhan Krishnan
10b5-1 checkbox reported
M · Exercise / conversion
Disposed
Performance share units
Derivative security
8100.00.0
2026-04-02
2026-04-06
Goff Brian
10b5-1 checkbox reported
S · Sale
Disposed
Common stock12472.034.71
2026-04-02
2026-04-06
Goff Brian
10b5-1 checkbox reported
S · Sale
Disposed
Common stock6596.034.71
2026-04-02
2026-04-06
Goff Brian
10b5-1 checkbox reported
M · Exercise / conversion
Acquired
Common stock25528.00.0
2026-04-02
2026-04-06
Goff Brian
10b5-1 checkbox reported
M · Exercise / conversion
Acquired
Common stock13500.00.0
2026-04-02
2026-04-06
Goff Brian
10b5-1 checkbox reported
M · Exercise / conversion
Disposed
Performance share units
Derivative security
13500.00.0
2026-04-02
2026-04-06
Goff Brian
10b5-1 checkbox reported
M · Exercise / conversion
Disposed
Performance share units
Derivative security
25528.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001439222AGIOS PHARMACEUTICALS, INC.

No parent relationship is available in this import; this is not proof of independence.

Legal Entity Identifier
529900ONJHY8EOGYT555
GLEIF legal name
Agios Pharmaceuticals, Inc.
Entity / LEI registration status
ACTIVE / LAPSED
Reference data updated
2021-07-19T05:07:28Z

direct-parent: no parent LEI supplied

ultimate-parent: no parent LEI supplied

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • Agios Pharmaceuticals · alias · wikidata
  • Agios Pharmaceuticals (United States) · alias · wikidata
  • AGIOS PHARMACEUTICALS INC · former SEC name · 2008-07-01 to 2019-07-16
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$36.50M$38.85M
2023-12-31$26.82M$29.39M
2022-12-31$14.24M$16.25M
2021-12-31$0$0
2020-12-31$0$0
2019-12-31$117.91M$154.00M
2018-12-31$94.39M$125.51M
2017-12-31$43.01M$58.59M

Bureau of Labor Statistics · retrieved 2026-09-07 · 9 selected series; gaps remain missing

Explore the CPI history ↗